IN Brief:
- Spanish ingredients supplier 3A Biotech is presenting BioSure Dry at Fi Europe 2026.
- The fermentation-derived preservative is intended to help control Listeria monocytogenes, although public product-specific efficacy data remain limited.
- EU rules applying since 1 July 2026 extend the circumstances in which ready-to-eat food producers must meet the absence criterion throughout shelf life.
Spanish ingredients supplier 3A Biotech is presenting a dry-format antimicrobial ingredient at Fi Europe 2026, targeting the control of Listeria monocytogenes in food formulations as manufacturers respond to stricter European microbiological requirements.
BioSure Dry is produced from fermentation extracts and is intended to help limit the growth of the pathogen in finished foods. 3A Biotech is showcasing the product during the Frankfurt exhibition, which runs from 17 to 19 November, alongside functional fibre blends used to modify texture and water retention.
The dry-format product extends the supplier’s existing BioSure preservation portfolio. The underlying antimicrobial range was introduced before November, making the presentation of BioSure Dry the current development rather than the initial launch of the preservation technology.
Nacho Ilzarbe, Head of Sales for 3A Biotech’s Human Food Division, identified Listeria control and changing regulatory requirements as central to the company’s product development. The formulation is positioned as a natural preservation option that can be incorporated into food manufacturing processes.
The exact composition of BioSure Dry has not been disclosed in the available technical information. The supplier describes its fermentation-derived origin, but has not identified the individual antimicrobial compounds, the recommended inclusion rates, or quantitative performance results for the new formulation.
Fermentation-derived preservation ingredients can contain substances produced through microbial metabolism. Their antimicrobial effects depend on the organisms and substrates used during fermentation, the composition of the recovered material, and the conditions in the food to which it is added.
Some fermentation-derived antimicrobials act by affecting microbial cell membranes or other processes essential to growth. That general mechanism does not establish which compounds are present in BioSure Dry or how its activity varies across different foods.
The target organism, Listeria monocytogenes, presents a significant control challenge because it can grow under suitable refrigerated conditions. Chilling slows the growth of many microorganisms, but it does not necessarily prevent the multiplication of Listeria in foods capable of supporting it.
Ready-to-eat products are particularly sensitive where the consumer is not expected to apply a further cooking or other lethal treatment before consumption. Contamination introduced after processing can persist through distribution if subsequent conditions permit microbial survival or growth.
The characteristics of the food influence the risk. Acidity, water activity, salt content, competing microorganisms, storage temperature, and the length of the intended shelf life all affect the potential for Listeria growth.
Formulation-based preservation must therefore be assessed within the complete product. Evidence that an antimicrobial ingredient performs under one set of conditions cannot automatically be applied to a different recipe or manufacturing process.
The regulatory framework has also changed. Commission Regulation (EU) 2024/2895, which began applying on 1 July 2026, amended the microbiological criteria for ready-to-eat foods capable of supporting the growth of Listeria monocytogenes.
Under the revised rules, the criterion requiring Listeria not to be detected in 25 grams applies throughout the shelf life of relevant products where the producing food business cannot demonstrate, to the satisfaction of the competent authority, that the organism will remain below 100 colony-forming units per gram.
The provisions concern specified ready-to-eat foods other than products intended for infants or for special medical purposes, which are subject to separate criteria. They do not impose one identical absence requirement on every food category regardless of its capacity to support microbial growth.
Manufacturers able to demonstrate that the applicable 100 cfu/g criterion will not be exceeded throughout shelf life can operate within that regulatory framework. Those unable to provide the required evidence must meet the stricter absence criterion during the period the relevant products are placed on the market.
This makes product-specific shelf-life evidence important. Depending on the characteristics of the food, manufacturers may use scientific information, durability studies, challenge tests, predictive models, and other appropriate evidence to establish whether the applicable microbiological criterion can be satisfied.
A preservation ingredient may contribute to that evidence where its effects have been established under the intended conditions. It cannot replace hygienic manufacturing practices, environmental monitoring, or the control of contamination during processing and packaging.
Equipment surfaces, product contact points, and handling operations remain potential routes through which microorganisms can enter finished foods. Effective sanitation and process controls are consequently necessary even where the formulation contains an antimicrobial ingredient.
The dry presentation of BioSure introduces a format that may suit existing ingredient batching and mixing systems. However, 3A Biotech has not disclosed the powder’s physical specifications, storage requirements, or behaviour during particular manufacturing processes.
Powder handling can involve considerations such as flowability, dust control, dispersion, and accurate dosing. Whether BioSure Dry offers advantages in these areas must be established from the properties of the product itself rather than inferred solely from its physical format.
The ingredient’s regulatory classification also requires verification for each intended application. Describing a preservative as natural or fermentation-derived does not establish that it is authorised for unrestricted use across all food categories or markets.
3A Biotech has previously promoted BioSure for applications involving meat products and other formulated foods. Its wider ingredients business develops preservative and antioxidant systems, supported by laboratory capabilities covering microbiology, analytical testing, and product stability.
The supplier is also expanding its fibre portfolio with blends intended to improve water retention, reduce syneresis, and modify food texture. These functions differ from antimicrobial preservation, although both can form part of the development of a finished product specification.
BioSure Dry’s current introduction establishes a new presentation within an existing antimicrobial portfolio. Broader industrial use will depend on documented efficacy under defined processing and storage conditions, the ingredient’s permitted regulatory status, and the ability to incorporate it without compromising the finished product’s required characteristics.


